Comparison · NCT01328093-49d34473
LY2140023-DB vs Aripiprazole-DB: Number of Participants With 30% or Greater Decrease in Positive and Negative Syndrome Scale (PANSS) Total Score
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. LY2140023-DB vs Aripiprazole-DB: Number of Participants With 30% or Greater Decrease in Positive and Negative Syndrome Scale (PANSS) Total Score. Trial comparisons, record NCT01328093-49d34473. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01328093-49d34473
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.274 | 0.236 | 0.315 | wilson | |
| Risk in group 2 | 0.316 | 0.248 | 0.393 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0425 | -0.128 | 0.0371 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.866 | 0.659 | 1.14 | log | |
| Odds ratio, group 1 over group 2 | 0.815 | 0.55 | 1.21 | log | |
| Number needed to treat, for one fewer participant with the outcome on LY2140023-DB than on Aripiprazole-DB | 23.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | LY2140023-DB | 40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily. | 133 | 486 | OG000 |
| Group 2 | Aripiprazole-DB | 15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily. | 49 | 155 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With 30% or Greater Decrease in Positive and Negative Syndrome Scale (PANSS) Total Score
- Description
The PANSS assesses the positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (absence of symptoms) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS Total Score and ranges from 30 to 210. Higher scores indicate greater severity of illness. Data presented are the number of participants with 30% or greater decrease from baseline in PANSS Total score.
- Time frame
- Baseline up to 24 weeks
- Population
Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, had a baseline and at least one post-baseline PANSS measurement, excluding participants from the excluded study site. Last observation carried forward (LOCF) principle was used.
Source ClinicalTrials.gov
Trial
- Title
- A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
- NCT number
- NCT01328093
- Phases
- PHASE3
- Conditions
- Schizophrenia
- Interventions
- LY2140023, Aripiprazole
- Lead sponsor
- Denovo Biopharma LLC
- Results first posted
- 2022-09-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01328093?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01328093-49d34473